The emerging role of glycolysis and immune evasion in ovarian cancer

Table 2 Compounds and their targets and experimental phases in OC therapy

Compounds	Target	Involvement of other factors	Experimental stage	References
PSVII	GLUT1	RORC/ACK1	In vitro and in vivo	18
PSVII	HK2	RORC/ACK1	In vitro and in vivo	18
NT1014	PDH	AMPK/mTOR	In vitro and in vivo	82
NT1014	LDHA	AMPK/mTOR	In vitro and in vivo	82
LY294002	PKM2	EGF/PI3K/AKT2	In vitro and in vivo	65
BAY-876	GLUT1	AMPK	In vitro and in vivo	174
2-DG	HK2	FAK/ERK1/2	In vitro and in vivo	116
DCA	PDK1	PD-1/PD-L1	In vitro and in vivo	175
AZD3965	MCT1	PD-1/PD-L1	In vivo	179
MLN0128	TORC1/2	/	Phase Ib	182
PP242	TORC1/2	AKT	In vitro and in vivo	183
ATG-008	TORC1/2	PD-1/PD-L1	Phase 1/2	181
AZD2014	TORC1/2	/	In vitro and in vivo	184
NVP-BEZ235	PI3K/mTOR	AKT	In vitro	185

ISSN: 1475-2867